Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Italy's biggest conglomerate, Intesa Sanpaolo, has paid 360 million euros ($382 million) in cash to acquire a 26.2% stake in health insurer Intesa Sanpaolo RBM Salute, which it does not own. that it will be used.
Read Full NewsNot all adrenal incidentalomas need the same workup. The Curbsiders break down when to worry, what to test, and why MACS may be behind your patient's hard-to-control metabolic disease.
Dr Maurie Markman examines new registry data on ovarian cancer diagnostic timing, showing how disease biology can complicate the link between early detection and survival.
Dr Andrea Chadwick describes how the shift from tender points to symptom-based criteria has improved fibromyalgia diagnosis, understanding, and patient-centered care.
Dr Anne Peters discusses the expanding use of continuous glucose monitoring in people with diabetes.
Before you freeze a skin lesion, ask yourself whether you really know what it is. Here are four signs you should biopsy instead of freeze.
EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision from causes unrelated to the targeted disease, sending its...
The FDA has approved a radioactive agent for use in brain scans to help assess patients for Alzheimer's disease.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
Q&A: When will individuals be able to receive customized cancer vaccines?
3.
Survivors of high-risk neuroblastoma face substantial late effects of modern therapies
4.
Cancer Patients Are Receiving More and More Stupid Immunotherapy.
5.
Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk
1.
Understanding Macrocytosis: Causes, Symptoms, and Treatment Options
2.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Potential of Device-Assisted Therapy in Non-Muscle-Invasive Bladder Cancer
5.
Building Physical Resilience in Chronic Blood Disorders
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
4.
Innovations in Hematology
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge